Shopping Cart
- Remove All
- Your shopping cart is currently empty
Lusvertikimab (OSE-127) is a humanized anti-IL7R antibody with anti-leukemic efficacy that reduces leukemic load in xenograft ALL through antibody-dependent phagocytosis and may be used to study leukemia.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $228 | In Stock | |
5 mg | $562 | In Stock | |
10 mg | $868 | In Stock | |
25 mg | $1,280 | In Stock | |
50 mg | $1,730 | In Stock |
Description | Lusvertikimab (OSE-127) is a humanized anti-IL7R antibody with anti-leukemic efficacy that reduces leukemic load in xenograft ALL through antibody-dependent phagocytosis and may be used to study leukemia. |
In vitro | Lusvertikimab inhibits STAT5 phosphorylation in IL7-dependent ALL cell lines and patient-derived xenograft (PDX) samples. [2] |
In vivo | Lusvertikimab-treated mice exhibited a reduction in peripheral hemoblasts in 95% of the xenograft (PDX) samples when control mice showed overt clinical signs of leukemia. [1] |
Alias | S-95011, S95011, OSE-127, OSE127 |
Cas No. | 2375835-91-7 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.